New hope for tough liver cancers: trial tests targeted drug combo
NCT ID NCT07493668
Summary
This study is for adults with advanced liver cancer (HCC) that has worsened after their first immunotherapy treatment. It will test if adding a new, liver-targeted oral drug called fostrox to the standard drug lenvatinib is more effective and safe than using lenvatinib alone. About 80 participants will be randomly assigned to one of the two treatment groups to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.